{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:40Z","timestamp":1788887080592,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the phase 4 BYOND trial, patients with pretreated chronic myeloid leukemia (CML) received bosutinib (starting dose: 500\u2009mg\/day). Efficacy and safety after \u22653 years of follow-up in 156 patients with Philadelphia chromosome\u2013positive chronic phase CML by age and Charlson Comorbidity Index scores (without the age component; mCCI) is reported. Cumulative major molecular response rates at any time on treatment were 73.6%, 64.5%, and 74.1% in patients &lt;65, 65\u201374, and \u226575 years of age, and 77.9%, 63.0%, and 59.3% in patients with mCCI scores 2, 3, and \u22654, respectively. Patients &lt;65, 65\u201374, and \u226575 years of age experienced grade 3\/4 treatment-emergent adverse events (TEAEs) at rates of 74.7%, 78.8%, and 96.4% and permanent discontinuations due to AEs at rates of 22.1%, 39.4%, and 46.4%, respectively. In patients with mCCI 2, 3, and \u22654, respective rates of grade 3\/4 TEAEs were 77.8%, 77.8%, and 86.7%, and permanent discontinuations due to AEs were 25.3%, 33.3%, and 43.3%. In conclusion, a substantial proportion of patients maintained\/achieved cytogenetic and molecular responses across age groups and mCCI scores. Older patients (\u226575 years) and those with high comorbidity burden (mCCI \u22654) may require more careful monitoring due to the increased risk of TEAEs. Clinicaltrials.gov: NCT02228382.<\/jats:p>","DOI":"10.1038\/s41375-023-02080-y","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:01:53Z","timestamp":1700913713000},"page":"126-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0310-4206","authenticated-orcid":false,"given":"Gianantonio","family":"Rosti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-3723","authenticated-orcid":false,"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn T.","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo-Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-2628","authenticated-orcid":false,"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-515X","authenticated-orcid":false,"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-8740","authenticated-orcid":false,"given":"Luke","family":"Kuttschreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"2080_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93:442\u201359.","journal-title":"Am J Hematol"},{"key":"2080_CR2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia (ver 1). 2019. https:\/\/jnccn.org\/view\/journals\/jnccn\/16\/9\/article-p1108.xml. Accessed 7 Jun 2022."},{"key":"2080_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood."},{"key":"2080_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"PA Pophali","year":"2016","unstructured":"Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22:40\u201350.","journal-title":"Cancer J"},{"key":"2080_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11899-018-0449-7","volume":"13","author":"JA Kennedy","year":"2018","unstructured":"Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase cml: strategies for frontline decision-making. Curr Hematol Malig Rep. 2018;13:202\u201311.","journal-title":"Curr Hematol Malig Rep"},{"key":"2080_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl J Med. 2002;346:645\u201352.","journal-title":"N. Engl J Med"},{"key":"2080_CR7","unstructured":"European Medicines Agency. Summary of product characteristics: Bosulif (bosutinib). 2018. https:\/\/www.ema.europa.eu\/documents\/product-information\/bosulif-epar-product-information_en.pdf. Accessed 7 Jun 2022."},{"key":"2080_CR8","unstructured":"US Food and Drug Administration. Highlights of prescribing information: Bosulif (bosutinib). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf. Accessed 10 Oct 2018."},{"key":"2080_CR9","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","volume":"118","author":"JE Cortes","year":"2011","unstructured":"Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118:4567\u201376.","journal-title":"Blood."},{"key":"2080_CR10","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","volume":"119","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012;119:3403\u201312.","journal-title":"Blood."},{"key":"2080_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3324\/haematol.2017.171249","volume":"103","author":"C Gambacorti-Passerini","year":"2018","unstructured":"Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, et al. Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study. Haematologica. 2018;103:1298\u2013307.","journal-title":"Haematologica."},{"key":"2080_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cncr.31082","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018;124:587\u201395.","journal-title":"Cancer."},{"key":"2080_CR13","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Br\u00fcmmendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125\u201337.","journal-title":"Leukemia."},{"key":"2080_CR14","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Br\u00fcmmendorf T, Abruzzese E, Kelly K, Oehler V, Garcia-Guti\u00e9rrez V, et al. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Blood. 2021;138:1475.","DOI":"10.1182\/blood-2021-150352"},{"key":"2080_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.leukres.2014.06.020","volume":"38","author":"M Breccia","year":"2014","unstructured":"Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, et al. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res. 2014;38:1173\u20136.","journal-title":"Leuk Res"},{"key":"2080_CR16","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1182\/blood-2019-129388","volume":"134","author":"FF Engelbrecht","year":"2019","unstructured":"Engelbrecht FF, Miranda EC, Delamain MT, Duarte GB, Souza CA, De Paula EV, et al. Impact of comorbidities on survival of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Blood. 2019;134:2938.","journal-title":"Blood."},{"key":"2080_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3109\/10428194.2014.993391","volume":"56","author":"M Breccia","year":"2015","unstructured":"Breccia M, Molica M, Colafigli G, Zacheo I, Latagliata R, Tafuri A, et al. Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. Leuk Lymphoma. 2015;56:2206\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2080_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1586\/17474086.2013.837279","volume":"6","author":"G Gugliotta","year":"2013","unstructured":"Gugliotta G, Castagnetti F, Fogli M, Cavo M, Baccarani M, Rosti G. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev Hematol. 2013;6:563\u201374.","journal-title":"Expert Rev Hematol"},{"key":"2080_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Sau\u00dfele","year":"2015","unstructured":"Sau\u00dfele S, Krau\u00df M-P, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126:42\u20139.","journal-title":"Blood."},{"key":"2080_CR20","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1111\/cas.14580","volume":"111","author":"T Ono","year":"2020","unstructured":"Ono T, Takahashi N, Kizaki M, Kawaguchi T, Suzuki R, Yamamoto K, et al. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor. Cancer Sci. 2020;111:3714\u201325.","journal-title":"Cancer Sci"},{"key":"2080_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377\u201386.","journal-title":"Cancer."},{"key":"2080_CR22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3324\/haematol.2011.041251","volume":"96","author":"M Breccia","year":"2011","unstructured":"Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, et al. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 2011;96:1457\u201361.","journal-title":"Haematologica."},{"key":"2080_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djr292","volume":"103","author":"P Le Coutre","year":"2011","unstructured":"Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"2080_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/ajh.22037","volume":"86","author":"KJ Aichberger","year":"2011","unstructured":"Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533\u20139.","journal-title":"Am J Hematol"},{"key":"2080_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","volume":"141","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745\u20137.","journal-title":"Br J Haematol"},{"key":"2080_CR26","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"2080_CR27","first-page":"1395","volume":"96","author":"P Valent","year":"2011","unstructured":"Valent P. Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematologica. 2011;96:1395\u20137.","journal-title":"Haematologica."},{"key":"2080_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","volume":"84","author":"M Breccia","year":"2012","unstructured":"Breccia M, Tiribelli M, Alimena G. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol. 2012;84:93\u2013100.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2080_CR29","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J Cortes","year":"2003","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, Giles F, Beth Rios M, Shan J, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105\u201313.","journal-title":"Cancer."},{"key":"2080_CR30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00432-017-2402-x","volume":"143","author":"FJ Giles","year":"2017","unstructured":"Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017;143:1585\u201396.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2080_CR31","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1182\/blood.V112.11.3233.3233","volume":"112","author":"JH Lipton","year":"2008","unstructured":"Lipton JH, le Coutre PD, Wang J, Yang M, Szczudlo T, Giles F. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood. 2008;112:3233.","journal-title":"Blood."},{"key":"2080_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-4-94","volume":"4","author":"WH Hall","year":"2004","unstructured":"Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer. 2004;4:94.","journal-title":"BMC Cancer"},{"key":"2080_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","volume":"15","author":"D Cella","year":"2012","unstructured":"Cella D, Jensen SE, Webster K, Hongyan D, Lai JS, Rosen S, et al. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire. Value Health. 2012;15:1051\u20138.","journal-title":"Value Health"},{"key":"2080_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012;36:438\u201342.","journal-title":"Leuk Res"},{"key":"2080_CR35","doi-asserted-by":"publisher","first-page":"106690","DOI":"10.1016\/j.leukres.2021.106690","volume":"111","author":"V Kota","year":"2021","unstructured":"Kota V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, Kim DW, An F, et al. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. Leuk Res. 2021;111:106690.","journal-title":"Leuk Res"},{"key":"2080_CR36","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"2080_CR37","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.2217\/fon-2019-0555","volume":"16","author":"C Gambacorti-Passerini","year":"2020","unstructured":"Gambacorti-Passerini C, le Coutre P, Piazza R. The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncol. 2020;16:4395\u2013408.","journal-title":"Future Oncol"},{"key":"2080_CR38","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","volume":"7","author":"A Zulbaran-Rojas","year":"2018","unstructured":"Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018;7:5457\u201369.","journal-title":"Cancer Med"},{"key":"2080_CR39","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"A Guerin","year":"2014","unstructured":"Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30:2317\u201328.","journal-title":"Curr Med Res Opin"},{"key":"2080_CR40","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"J Cortes","year":"2020","unstructured":"Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136:2507\u201312.","journal-title":"Blood."},{"key":"2080_CR41","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia."},{"key":"2080_CR42","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1182\/blood-2021-151240","volume":"138","author":"S Isfort","year":"2021","unstructured":"Isfort S, Wolf D, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, et al. Step-in Dosing in the Bosutinib Dose Optimization study (BODO) failed to reduce gastrointestinal (GI) toxicity in patients failing second generation TKI (2G-TKI) in chronic phase chronic myeloid leukemia (CML) but suggests promising molecular response. Blood. 2021;138:3608.","journal-title":"Blood."},{"key":"2080_CR43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2019-127514","volume":"134","author":"F Castagnetti","year":"2019","unstructured":"Castagnetti F, Gugliotta G, Bocchia M, Trawinska MM, Capodanno I, Bonifacio M, et al. Dose optimization in elderly CML patients treated with bosutinib after intolerance or failure of first-line tyrosine kinase inhibitors. Blood. 2019;134:496.","journal-title":"Blood."},{"key":"2080_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hon.2851","volume":"39","author":"R Latagliata","year":"2021","unstructured":"Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C, et al. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant\/intolerant to previous tyrosine-kinase inhibitors. Hematol Oncol. 2021;39:401\u20138.","journal-title":"Hematol Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02080-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02080-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02080-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:08:28Z","timestamp":1704809308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02080-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2080"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02080-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"25 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GR received research support from Pfizer and served on the speaker bureau for Bristol Myers Squibb, Incyte, Novartis, and Pfizer. THB provides consultancy to Janssen, Merck, Novartis, Pfizer, and Takeda, and received research support from Novartis and Pfizer. BTG provides consultancy to BerGenBio, Novartis, Pfizer, and Sanofi, received research support from Pfizer, and has stock ownership in Alden Cancer Therapy AS and KinN Therapeutics AS. PG-C received research support from Bristol Myers Squibb and Pfizer. FC provides consultancy to and received honoraria from Bristol Myers Squibb, Incyte, Novartis, and Pfizer, and received research support from Pfizer. CG-P provides consultancy to Bristol Myers Squibb and received honoraria and research support from Pfizer. TE, no relationships to disclose. HZ, LK, and SP are employees of Pfizer. FJG provided consultancy to Actuate Therapeutics Inc, provided expert testimony to Novartis, and received research support from Pfizer. AH received research support from Bristol Myers Squibb, Incyte, Novartis, and Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}